Clik here to view.
More trouble for United’s Remodulin
The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office ruled yesterday that the claims of United Therapeutics‘s (NSDQ:UTHR) patent, which covers Remodulin, are unpatenable due to...
View ArticleClik here to view.
Study: Nanoparticles could improve efficacy of cancer immunotherapy
Researchers from the University of North Carolina have discovered that they can potentially improve cancer immunotherapy drugs by binding 2 compounds to a single nanoparticle. The team’s work was...
View ArticleClik here to view.
Acorda to cut 20% of staff in restructuring effort
Acorda Therapeutics (NSDQ:ACOR) said today that it plans to cut 20% of its workforce as a part of a cost reduction and restructuring effort. The move comes less than 1 week after the company lost...
View ArticleClik here to view.
Actelion shareholders OK R&D spinout
Actelion (VTX:ATLN) shareholders today reportedly approved spinning off the company’s early clinical assets and drug discovery branch into a new company. The move keeps Johnson & Johnson (NYSE:JNJ)...
View ArticleClik here to view.
Therapix, Yissum ink nasal drug delivery pact
Therapix Biosciences (NSDQ:TRPX) said today that it inked a sublicense agreement for nasal drug delivery tech from Yissum Research Development Company at the Hebrew University. According to the deal,...
View ArticleClik here to view.
Liposomal drug delivery system could improve solid tumor treatment
The oxygen-poor regions of solid tumors usually help make them resistant to chemotherapy and other forms of treatment. But researchers at Oregon State University have devised away to take advantage of...
View ArticleClik here to view.
Triple inhaler reduces COPD flare-ups by 20%
Researchers at the University of Manchester found that flare-ups in chronic obstructive pulmonary disease can be reduced by 20% with a combined triple inhaler. The team’s work was published in the...
View ArticleClik here to view.
SteadyMed studies accuracy and precision of PatchPump infusion system for...
SteadyMed (NSDQ:STDY) said yesterday that it finished a clinical study for its lead drug candidate, Trevyent. The pulmonary arterial hypertension treatment is a combination of treprostinil and the...
View ArticleClik here to view.
B. Braun launches app for Easypump home infusion therapy
B. Braun launched an app yesterday for its Easypump ST/LT elastomeric infusion pump to help patients and clinicians use the system more safely and efficiently for home infusion therapy. The Easypump...
View ArticleClik here to view.
German billionaire Hopp readies sale of skin patch maker LTS
German billionaire Dietmar Hopp is reportedly preparing to sell medical skin patch maker LTS Lohmann as he looks to shake-up his investment porfolio. LTS has 1,300 employees and brings in more than 300...
View ArticleClik here to view.
AcelRx touts data from Dsuvia pain relief trials
AcelRx Pharmaceuticals (NSDQ:ACRX) touted efficacy and safety data today for its pain reliever, Dsuvia. The company’s lead drug candidate is composed of 30 sufentanil tablets delivered sublingually...
View ArticleClik here to view.
Homing system targets drugs to individual neurons
Researchers from Duke University and the Howard Hughes Medical Institute have developed a technique to target and deliver drugs to specific types of neurons in the brain. The team argues that this will...
View ArticleClik here to view.
Keystone Nano launches clinical trial for NanoLiposome cancer therapy
Keystone Nano said today that it has begun clinical testing for its ceramide NanoLiposome cancer therapy. The Phase I trial plans to evaluate the company’s NanoLiposome as a targeted treatment for...
View ArticleClik here to view.
Patients twice as likely to take anticoagulants with artificial intelligence...
Researchers from the Stern Stroke Center at Montefiore Medical Center published trial results this week showing that stroke survivors were twice as likely to take anticoagulants when using an...
View ArticleClik here to view.
After review of patient deaths, European regulators OK Actelion’s Uptravi
The European Medicines Agency told doctors today that they can continue to prescribe Actelion‘s (VTX:ATLN) pulmonary arterial hypertension drug, Uptravi. The regulatory body initiated a safety review...
View ArticleClik here to view.
Report: Fresenius set to buy generics maker Akorn
German healthcare group Fresenius SE (NYSE:FMS) reportedly said last week that it is in talks with generic drugmaker Akorn Inc. (NSDQ:AKRX) for a potential takeover. Akorn shares jumped 10% to $32.60...
View ArticleClik here to view.
European countries vie to host drug agency after Brexit
The European Medicines Agency said it has heard from 21 countries that want to host the London-based regulator once Britain leaves. The EMA is preparing to leave its headquarters as a result of Brexit...
View ArticleClik here to view.
Nanoparticles permeate lungs to deliver pulmonary drugs
Researchers from Johns Hopkins University have developed nanoparticles that can shuttle chemicals through the thick mucus membranes of pulmonary airways to deliver drugs. The team’s work was published...
View ArticleClik here to view.
CRISPR uncovers drug compounds in bacterial genome
Researchers at the University of Illinois and the Agency for Science, Technology & Research in Singapore are using the gene-editing tool CRISPR-Cas9 to uncover potentially useful drug compounds....
View ArticleClik here to view.
CareFusion recalls IV sets on cracked back-check valves
Becton Dickinson subsidiary CareFusion recalled some IV sets today after reports that cracks in the secondary set back-check valve caused infusion fluid to leak. The company said the secondary sets are...
View Article